2023 World Conference on Lung Cancer (Posters)-P1.27. Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials

P1.27. Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials - PDF(Abstract)

Back to course

Pdf Summary

This abstract presents a meta-analysis comparing the effectiveness of immunotherapy (immunotherapy with or without chemotherapy) versus chemotherapy alone in the treatment of resectable non-small cell lung cancer (NSCLC). The study aimed to determine the overall survival (OS) and disease-free survival (DFS) outcomes in patients receiving either neoadjuvant or adjuvant immunotherapy.<br /><br />A total of 9,375 articles were screened, and four studies were included in the analysis. The results showed that patients receiving neoadjuvant immunotherapy with chemotherapy had improved OS and DFS compared to those receiving chemotherapy alone. The pooled hazard ratio (HR) for OS was 0.53 and for DFS was 0.60. In contrast, for adjuvant immunotherapy with chemotherapy, the OS benefit was not statistically significant, but there was a significant improvement in DFS, with a pooled HR of 0.77.<br /><br />Further analysis found significantly improved OS in the subgroup of patients with positive PD-L1 status and non-squamous histology. However, the addition of immunotherapy did not significantly improve OS in PD-L1 negative and squamous histology tumors. The mutational status of EGFR did not impact DFS or OS in patients receiving adjuvant immunotherapy.<br /><br />Overall, the meta-analysis suggests that both neoadjuvant and adjuvant immunotherapy can improve OS and DFS in patients with early-stage, resectable NSCLC, particularly in those with positive PD-L1 status and non-squamous histology. Further research and ongoing trials are needed to better understand the role of immunotherapy in this clinical scenario.<br /><br />Keywords: immune checkpoint inhibitor, neoadjuvant, adjuvant.

Asset Subtitle

Ben Ponvilawan

Meta Tag

Speaker Ben Ponvilawan

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

immunotherapy

chemotherapy

non-small cell lung cancer

resectable

overall survival

disease-free survival

neoadjuvant

adjuvant

PD-L1 status

squamous histology